Literature DB >> 28463034

Altered miRNA expression in aniline-mediated cell cycle progression in rat spleen.

Gangduo Wang1, Jianling Wang1, M Firoze Khan1.   

Abstract

Aniline exposure is associated with toxicity to the spleen, however, early molecular events in aniline-induced cell cycle progression in the spleen remain unknown. MicroRNAs (miRNAs) have been implicated in tumor development by modulating key cell cycle regulators and controlling cell proliferation. This study was, therefore, undertaken on the expression of miRNAs, regulation of cyclins and cyclin-dependent kinases (CDKs) in an experimental condition that precedes a tumorigenic response. Male SD rats were treated with aniline (1 mmol/kg/day by gavage) for 7 days, and expression of miRNAs, cyclins and CDKs in rat spleens were analyzed. Microarray and/or qPCR analyses showed that aniline exposure led to significantly decreased miRNA expression of let-7a, miR-24, miR-34c, miR-100, miR-125b, and greatly increased miR-181a. The aberrant expression of miRNAs was associated with significantly increased protein expression of cyclins A, B1, D3 and E. Furthermore, remarkably enhanced expression of CDKs like CDK1, CDK2, CDK4, CDK6, especially p-CDK1 and p-CDK2 as well as alternations in the expression of pRB, p27, and CDC25A in the spleens of aniline-treated rats was also observed. The data suggest that aniline exposure leads to aberrant expression of miRNAs in the spleen which could be important in the regulation of cell cycle proteins. Our findings, thus, provide new insight into the role of miRNAs in cell cycle progression, which may contribute to aniline-induced tumorigenic response in the spleen.

Entities:  

Keywords:  Aniline; cell cycle; cyclin; cyclin-dependent kinase; miRNA; spleen

Mesh:

Substances:

Year:  2017        PMID: 28463034      PMCID: PMC6295204          DOI: 10.1080/15376516.2017.1324932

Source DB:  PubMed          Journal:  Toxicol Mech Methods        ISSN: 1537-6516            Impact factor:   2.987


  45 in total

Review 1.  Control of the G2/M transition.

Authors:  George R Stark; William R Taylor
Journal:  Mol Biotechnol       Date:  2006-03       Impact factor: 2.695

2.  Iron release and oxidative DNA damage in splenic toxicity of aniline.

Authors:  Xiaohong Wu; Subburaj Kannan; V M Sadagopa Ramanujam; M Firoze Khan
Journal:  J Toxicol Environ Health A       Date:  2005-04-23

Review 3.  To cycle or not to cycle: a critical decision in cancer.

Authors:  M Malumbres; M Barbacid
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 4.  RB and cell cycle progression.

Authors:  C Giacinti; A Giordano
Journal:  Oncogene       Date:  2006-08-28       Impact factor: 9.867

5.  Up-regulation of transforming growth factor-beta 1 in the spleen of aniline-treated rats.

Authors:  M Firoze Khan; Xiaohong Wu; Jianling Wang
Journal:  Toxicol Appl Pharmacol       Date:  2003-02-15       Impact factor: 4.219

6.  Activation of transcription factor AP-1 and mitogen-activated protein kinases in aniline-induced splenic toxicity.

Authors:  M Firoze Khan; Subburaj Kannan; Jianling Wang
Journal:  Toxicol Appl Pharmacol       Date:  2005-09-19       Impact factor: 4.219

7.  Iron exacerbates aniline-associated splenic toxicity.

Authors:  M F Khan; X Wu; N W Alcock; P J Boor; G A Ansari
Journal:  J Toxicol Environ Health A       Date:  1999-06-11

8.  Cytokine gene expression and activation of NF-kappa B in aniline-induced splenic toxicity.

Authors:  Jianling Wang; Subburaj Kannan; Hui Li; M Firoze Khan
Journal:  Toxicol Appl Pharmacol       Date:  2005-02-15       Impact factor: 4.219

9.  Superoxide signaling mediates N-acetyl-L-cysteine-induced G1 arrest: regulatory role of cyclin D1 and manganese superoxide dismutase.

Authors:  Sarita G Menon; Ehab H Sarsour; Amanda L Kalen; Sujatha Venkataraman; Michael J Hitchler; Frederick E Domann; Larry W Oberley; Prabhat C Goswami
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 10.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.